Colchicine use might be associated with lower mortality in COVID-19 patients: A meta-analysis.

We read with great interest the recently published meta-analysis by Aimo et al. in the European Journal of Clinical Investigation.1 The analysis encompassing over 5000 patients' data revealed a significant reduction in adverse cardiovascular events in patients with chronic coronary syndrome receiving colchicine vs. control. These results are promising and suggest a potential role for colchicine in treating thrombogenic conditions. Colchicine is an ancient anti-inflammatory agent with an established safety profile. It inhibits various inflammatory pathways, including neutrophils adhesion, inflammasome activation, microtubule formation, neutrophil extracellular traps (NETs) essential in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesis. 2 3 Coronavirus disease 2019 (COVID-19) is thought to be associated with an exaggerated inflammatory response and thrombogenicity.4 Thus, studies tested repurposing this medication in the treatment of COVID-19 and yielded promising results.5,6. This article is protected by copyright. All rights reserved.